Detalhe da pesquisa
1.
Bivalent Omicron BA.1-Adapted BNT162b2 Booster in Adults Older than 55 Years.
N Engl J Med
; 388(3): 214-227, 2023 01 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-36652353
2.
Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age.
N Engl J Med
; 388(7): 621-634, 2023 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36791162
3.
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.
Nature
; 586(7830): 589-593, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32785213
4.
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
N Engl J Med
; 386(1): 35-46, 2022 01 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34752019
5.
Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine.
N Engl J Med
; 386(20): 1910-1921, 2022 05 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35320659
6.
A Phase 2 Extension Study Evaluating the Immunogenicity, Safety, and Tolerability of 3 or 4 Doses of a Clostridioides difficile Vaccine in Healthy US Adults Aged 65 to 85 Years.
J Infect Dis
; 229(2): 367-375, 2024 Feb 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37531657
7.
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.
N Engl J Med
; 385(3): 239-250, 2021 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34043894
8.
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months.
N Engl J Med
; 385(19): 1761-1773, 2021 11 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34525277
9.
A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-Olds.
Clin Infect Dis
; 2023 Nov 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38016021
10.
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
N Engl J Med
; 383(27): 2603-2615, 2020 12 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-33301246
11.
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.
N Engl J Med
; 383(25): 2439-2450, 2020 12 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-33053279
12.
Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.
Nature
; 590(7844): E26, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33469216
13.
Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine.
N Engl J Med
; 388(9): 854-857, 2023 Mar 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36734885
14.
A Phase 2 Study Evaluating the Safety, Tolerability, and Immunogenicity of Two 3-Dose Regimens of a Clostridium difficile Vaccine in Healthy US Adults Aged 65 to 85 Years.
Clin Infect Dis
; 70(1): 1-10, 2020 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31125055
15.
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.
N Engl J Med
; 385(17): 1627-1629, 2021 10 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-34525276
16.
Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial.
Vaccines (Basel)
; 12(2)2024 Jan 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38400102
17.
Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination.
Infect Dis Ther
; 13(4): 699-714, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38489117
18.
A phase 3 study evaluating the lot consistency, immunogenicity, safety, and tolerability of a Clostridioides difficile vaccine in healthy adults 65 to 85 years of age.
Vaccine
; 41(50): 7548-7559, 2023 Dec 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37977942
19.
Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults.
Infect Dis Ther
; 12(9): 2241-2258, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37698774
20.
Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds.
J Pediatric Infect Dis Soc
; 12(4): 234-238, 2023 Apr 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36929216